AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03303989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF
Description: Participants randomized to the pegloticase + MMF arm will start two week run-in on 1) mycophenolate mofetil at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period, Mycophenolate mofetil therapy will continue for 12 weeks at the highest tolerated dose. After the 12-week combination mycophenolate mofetil and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
Study NCT03303989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to the pegloticase + placebo arm will start two week run-in on 1) placebo at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period. After the 12-week combination placebo and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
Study NCT03303989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegloticase 8 MG/ML [Krystexxa]
Description: Participants randomized to the pegloticase + placebo arm will start two week run-in on 1) placebo at 500 mg/BID or the first week, titrating dose up to 1000mg/BID for the second week of run-in prior to the first infusion; and 2) Pegloticase 8 mg IV every two weeks following 2 week run-in period. After the 12-week combination placebo and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
Study NCT04522869 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation
Description: Umbilical Cord Derived Mesenchymal Stem Cell (UC -MSC) Transplantation for Children Suffering From Liver Cirrhosis Due to Biliary Atresia
Study NCT00142948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: naltrexone
Study NCT00142948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT02298114 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEUROMUSCULAR ELECTRICAL STIMULATION
Description: Neuromuscular electrical stimulation will be applied Functional Electrical Stimulation (FES) machine.
Study NCT02298114 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional physiotherapy
Description: The control group will receive conventional physiotherapy associated the placebo electrical stimulation
Study NCT01278290 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin acetate and Gonadorelin acetate
Description: Triptorelin acetate test, using aqueous 0.1 mg/m2 subcutaneous. Gonadorelin test using 100 ug intravenous.
Study NCT01278290 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Gonadorelin acetate and Triptorelin acetate
Description: Gonadorelin acetate intravenous 100 ug. Triptorelin acetate 100 ug/m2.
Study NCT02406625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Therapy
Description: 16 therapeutic group sessions are delivered to both parents and adolescents; according to the assigned group for each family.
Study NCT02160925 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative 99mTc-Sestamibi SPECT/CT
Study NCT02255097 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Study NCT02511782 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: D-SQUAME Skin Sampling Discs
Description: A D-SQUAME Skin Sampling Disc is a noninvasive patch that collects skin cell samples when affixed to the superficial stratum corneum (top layer of skin). The patch is applied with gentle pressure to the desired quadrant of the forearm and removed 2 minutes after application.
Study NCT02511782 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: D-SQUAME Skin Sampling Discs
Description: A D-SQUAME Skin Sampling Disc is a noninvasive patch that collects skin cell samples when affixed to the superficial stratum corneum (top layer of skin). The patch is applied with gentle pressure to the desired quadrant of the forearm and removed 2 minutes after application.
Study NCT01448902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC000459
Description: OC000459 200mg bid for 8 days
Study NCT01448902 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo bid for 8 days
Study NCT01980693 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SonicBone ultrasound
Description: The device measure BA using ultrasound technology by measurement of speed of sound in three different sites : wrist bones, Phalanx III, Metacarpal bones.The device sends a short US pulse and measures the distance between a transmitter probe and a receiver probe, located at the bone measured area.The US probe converts electrical pulse to US pulse and US wave via tested bone arrives from transmitter to Receiver. Simultaneously with US pulse, controller start timer to calculate time between US pulse and the moment that US wave arrives to receiver. The accepted US signal of selected probe via amplifiers arrives to comparators that read timer value. The microcontroller calculates SOS using distance between probes and US time of flight.
Study NCT01033305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CyCol™
Description: Orally, once per day for 4 weeks
Study NCT01033305 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally, once per day for 4 weeks
Study NCT02006160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dalfampridine
Description: 10 mg bid
Study NCT02006160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 10 mg bid
Study NCT02524197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CR845 0.25 mg
Description: Subjects will dose orally twice a day with CR845 0.25 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
Study NCT00649597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lotensin HCT® Tablets 20 mg/25 mg
Description: 20/25mg, single dose fasting
Study NCT00770380 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavioral relapse prevention counseling
Description: Behavioral relapse prevention counseling conducted in two one-hour sessions
Study NCT02524197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CR845 0.50 mg
Description: Subjects will dose orally twice a day with CR845 0.50 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
Study NCT02524197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CR845 1 mg
Description: Subjects will dose orally twice a day with CR845 1 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
Study NCT02524197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CR845 5 mg
Description: Subjects will dose orally twice a day with CR845 5 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
Study NCT05470972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol Injection
Description: The AEST procedure was performed as follows: vaginal walls were cleansed using vaginal povidone-iodine, a 17 gauge, 30-cm length needle was inserted through the posterior vaginal fornix into the pouch of Douglas, and the cyst was aspirated till complete disappearance of the cyst on the ultrasound scanner. The collected cystic fluid was collected into a plastic tube without an anticoagulant. The needle was maintained in its place, the syringe was removed and the cyst was flushed with saline solution until obtaining a clear liquid. Then, 96% ethanol was injected as 60% of the volume of the aspirated fluid to guard against over distension or rupture of the cyst and/or ethanol diffusion into the pelvis. The collected fluid was divided into three sterile tubes for cytological and bacteriological examinations and the study investigations. Patients were allowed to be completely recovered and were discharged home.
Study NCT02520986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon dioxide Laser ablation
Description: surgical Instrument to achieve excision of genital warts by a pulsed laser of 15 Watt voltage
Study NCT02520986 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocoagulation
Description: surgical Instrument to achieve excision of genital warts by a deep tissue electrocoagulation of 80 Watt voltage
Study NCT00770380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypnosis for relapse prevention
Description: Hypnosis for relapse prevention conducted in two one-hour sessions
Study NCT03772327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adheretech smart bottle
Description: A smart pill bottle that measures the exact number of pills in the bottle in real-time, sends this HIPAA-compliant data to a central server, and based on the results, can remind participants to take their medication through a phone call or text message.
Study NCT04861402 — intervention group
Intervention type: DEVICE
Intervention: The ICP monitoring will be performed in a non-invasive method developed by Brain4Care
Description: The ICP monitoring will be performed in a non-invasive way through the cranial deformation method developed by Brain4Care Inc.~The selected patients will be monitored until 1h/day for 7 sequential days or even discharge. The clinical outcomes such as ventilatory status will be noted (if the subject is under oxygen supplementation, using non-invasive mechanical ventilation or intubated), the ventilatory parameters during the monitorization will be analyzed in the intubated group (or those from a non-intubated group who was intubated during the seven days of hospitalization) including IFO2, CV, PEEP, driving pressure, and pressure plate as well as ventilatory asynchronies. Some changes in ventilatory parameters during monitorization will be noted. These procedures will be applied to all groups, excepted to the healthy group. This last group will be monitored only once for 30 minutes at the Federal University of São Carlos (UFSCar).
Study NCT03179202 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPRINT Peripheral Nerve Stimulation (PNS) System
Description: The SPRINT PNS System is a device which delivers mild electrical stimulation to the muscles in the low back. The System includes up to four small wires (called Leads) that are placed through the skin into the muscles in the low back. The wires attach to device(s) worn on the body that deliver stimulation (called Stimulators). The PNS System was approved by the FDA for up to 60 days of use for the management of acute and chronic pain, including back pain.
Study NCT03772327 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine adherence counseling
Description: Participants will be provided with routine adherence counseling
Study NCT03772327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine adherence counseling
Description: Participants will be provided with routine adherence counseling
Study NCT00130247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: Mycobacteriostatic agent given to prevent emergence of drug resistance to other 1st line drugs; dosages are 15-25 milligram (mg)/ kilogram (kg)/day (d).
Study NCT00130247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethambutol
Description: Mycobacteriostatic agent given to prevent emergence of drug resistance to other 1st line drugs; dosages are 15-25 milligram (mg)/ kilogram (kg)/day (d).
Study NCT00130247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Hydrazide of isonicotininc acid; antimicrobial activity is limited to mycobacteria where it inhibits the synthesis of mycolic acids.
Study NCT00130247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid
Description: Hydrazide of isonicotininc acid; antimicrobial activity is limited to mycobacteria where it inhibits the synthesis of mycolic acids.
Study NCT00130247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: 1st line bactericidal agent; dosages are 15-30 mg/kg/d, up to 2 grams (gm)/d.
Study NCT00130247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyrazinamide
Description: 1st line bactericidal agent; dosages are 15-30 mg/kg/d, up to 2 grams (gm)/d.
Study NCT00130247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 1st line bactericidal agent which inhibits deoxyribonucleic acid (DNA)-dependent ribonucleic acid (RNA) polymerase; dosages are 10 mg/kg/d (up to 600 mg/d).
Study NCT00130247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: 1st line bactericidal agent which inhibits deoxyribonucleic acid (DNA)-dependent ribonucleic acid (RNA) polymerase; dosages are 10 mg/kg/d (up to 600 mg/d).
Study NCT00525577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet, once daily
Study NCT00525577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGI-1067
Description: 75 mg AGI-1067 tablet, once daily
Study NCT00525577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGI-1067
Description: 150 mg AGI-1067 Tablet, once daily
Study NCT02423096 — intervention group
Intervention type: DRUG
Intervention: Risperidone
Description: Patients with schizophrenia will be treated with antipsychotic drugs as routine care.
Study NCT01016626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-4101 tablet
Description: CKD-4101 tablet 1000 mg~* 500mg/tablet, PO, 2 tablet once daily for D1 and D8(crossover)
Study NCT01016626 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil capsule
Description: Mycophenolate Mofetil capsule 1000 mg~* 250mg/capsule, PO, 4 capsule once daily for D1 and D8(crossover)
Study NCT01658514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Met DR
Description: metformin delayed-release tablets
Study NCT01658514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Met XR
Description: metformin extended-release tablets
Study NCT01658514 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03589001 — intervention group
Intervention type: OTHER
Intervention: Activity modification
Description: Activity modification, exercises and gradual return to sport
Study NCT02222402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INTRA-DIALYTIC EXERCISE TRAINING
Study NCT03452267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: oral, 850 mg twice daily
Study NCT03452267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: oral, 45 mg daily
Study NCT03452267 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, once daily
Study NCT04294485 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: Electrostimulation combined with exercise
Study NCT00484315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation
Description: TAXUS Element stent placement
Study NCT00484315 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Express) placement
Description: TAXUS Express Stent Implant
Study NCT02344576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DT LVAD Decision Support Intervention
Description: Decision coaching and training of staff prior to intervention, to allow for additional decision support to patients and caregivers considering DT LVAD. Decision aid materials will be used with patients and caregivers.
Study NCT02022826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartPill Monitoring System
Study NCT03306654 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Happify
Description: An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
Study NCT03306654 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Happify
Description: An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
Study NCT03306654 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Happify
Description: An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
Study NCT04334382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Patients in the hydroxychloroquine arm will receive hydroxychloroquine 400mg po BID x 1 day, then 200mg po BID x 4 days (dose reductions for weight \< 45kg). The drug dose (2.4 gm over 5 days) chosen falls at the lower end of doses proposed in various international trials, but it has proven in vitro efficacy, with a ratio of lung tissue trough concentrations to the EC50 (effective concentration to suppress 50% of viral activity) of >20.
Study NCT04334382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Patients in the azithromycin arm will receive azithromycin 500mg PO on day 1 plus 250mg PO daily on days 2-5.
Study NCT00748657 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT00748657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT04523740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients who use regular paracetamol will now receive 6 to 8 tablets of placebo per day for 2 weeks
Study NCT04523740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Patients who use regular paracetamol will now receive 6 to 8 tablets of 500 mg paracetamol per day for 2 weeks
Study NCT00730340 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closure of the Tonsillar Fossa
Description: We hypothesize that closure of the tonsillar fossa decreases the morbidity of pain by decreasing exposure of the raw operative bed to oral secretions, mediation, and oral intake, and decreases the morbidity of post-operative hemorrhage by having the operative wound closed.
Study NCT00730340 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tonsillectomy with open fossa
Description: SOP for a tonsillectomy.
Study NCT03140319 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibroblast
Description: Transplantation of 20 million cell by three injection
Study NCT03140319 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of Placebo
Study NCT02210338 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Karl Storz C-MAC
Study NCT02210338 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bonfils Intubation Fibrescope
Study NCT03170830 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: the diagnosis value of cUck2 in acute myocardial infarction.
Description: Collect blood at different time points and compare cUck2 in three groups.
Study NCT01856114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Buccal Tablet
Description: Fentanyl buccal tablet given to put in between upper gum and cheek one hour after a six minute walk test.
Study NCT01856114 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Buccal Tablet
Description: Placebo buccal tablet given to put in between upper gum and cheek one hour after a six minute walk test.
Study NCT01856114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.
Study NCT01856114 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.
Study NCT01245673 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar- Pneumococcal Conjugate Vaccine (PCV)
Description: After study enrollment, patients will receive Prevnar- Pneumococcal Conjugate Vaccine (PCV). At Day #14, Day #42, and Day #90, Day #120 and Day #150, patients will receive a booster immunization with Prevnar- Pneumococcal Conjugate Vaccine (PCV).
Study NCT03726450 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Andrositol Plus
Description: Myo-inositol
Study NCT03726450 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Andrositol Plus
Description: N-Acetyl-Cysteine
Study NCT01245673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activated/costimulated autologous T-cell
Description: For all patients, the cells will be expanded ex vivo for up to 12 days and then prepared for infusion \~day 2 post-transplant. The target number of costimulated T-cells for infusion will be \~ 5 x 10e10 T-cells total in 100-500 mL total volume.